查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1212227

類風濕性關節炎治療的全球市場

Rheumatoid Arthritis Therapeutics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 150 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球類風濕性關節炎治療的市場規模預測將從2022年的483億美元，到2030年達到667億美元，在2022年～2030年間預計將以4.1％的年複合成長率成長。

本報告提供全球類風濕性關節炎治療市場相關調查分析，提供市場概要，市場趨勢，各地區的市場分析，競爭情形等系統性資訊。

調查對象企業範例(計23公司):

  • AbbVie, Inc.
  • Amgen, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • UCB SA

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP-1498

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Rheumatoid Arthritis Therapeutics Market to Reach $66.7 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Rheumatoid Arthritis Therapeutics estimated at US$48.3 Billion in the year 2022, is projected to reach a revised size of US$66.7 Billion by 2030, growing at aCAGR of 4.1% over the period 2022-2030. Pharmaceuticals, one of the segments analyzed in the report, is projected to record 4% CAGR and reach US$28 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Biopharmaceuticals segment is readjusted to a revised 4.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $13.2 Billion, While China is Forecast to Grow at 6.9% CAGR

The Rheumatoid Arthritis Therapeutics market in the U.S. is estimated at US$13.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.8 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 3.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Select Competitors (Total 23 Featured):

  • AbbVie, Inc.
  • Amgen, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Novartis International AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • UCB SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Rheumatoid Arthritis Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Rheumatoid Arthritis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Biopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Biopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Biopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Prescription by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Over-the-Counter (OTC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Rheumatoid Arthritis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • JAPAN
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • CHINA
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: China 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: China 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • EUROPE
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Rheumatoid Arthritis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • FRANCE
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: France 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: France 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • GERMANY
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Rheumatoid Arthritis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • INDIA
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: India 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: India 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Rheumatoid Arthritis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Rheumatoid Arthritis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030
  • AFRICA
    • Rheumatoid Arthritis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Rheumatoid Arthritis Therapeutics by Molecule Type - Pharmaceuticals and Biopharmaceuticals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Pharmaceuticals and Biopharmaceuticals for the Years 2014, 2023 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Rheumatoid Arthritis Therapeutics by Sales Channel - Prescription and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Rheumatoid Arthritis Therapeutics by Sales Channel - Percentage Breakdown of Value Sales for Prescription and Over-the-Counter (OTC) for the Years 2014, 2023 & 2030

IV. COMPETITION